Description Results NMA

heart failure 0.80 [0.65; 0.98]

all cause death 1.05 [0.92; 1.19]

coronary heart disease 0.87 [0.73; 1.05]

cardiovascular death 1.06 [0.89; 1.27]

stroke (fatal & non fatal) 1.03 [0.86; 1.24]

Major cardiovascular events 0.94 [0.85; 1.04]

Enalapril or lisinopril , enalapril 10 mg or lisinopril 10 mg daily (n=2205)

vs.

felodipine 2.5 mg or isradipine 2-5 mg daily (n=2196)

Open

Parallel groups

Sample size: 2205/2196

Primary endpoint:

FU duration: 5·0 y

ACE inhibitor (n=-9)

vs.

nifedipine (n=-9)

Open

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 3·0 y

heart failure 0.63 [0.52; 0.77]

all cause death 1.02 [0.77; 1.35]

coronary heart disease 0.90 [0.74; 1.09]

cardiovascular death 1.01 [0.72; 1.42]

stroke (fatal & non fatal) 0.90 [0.74; 1.09]

MI (all) 0.90 [0.74; 1.09]

Major cardiovascular events 0.94 [0.71; 1.24]

enalapril 10 mg or lisinopril10 mg daily (n=2205)

vs.

conventional antihypertensive drugs (atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or hydrochlorothiazide 25 mg plus amiloride 2·5 mg daily) (n=2213)

Open

Parallel groups

Sample size: 2205/2213

Primary endpoint: fatal stroke, fatal MI, other cardiovascular death

FU duration: 5.0 y